Sichenzia Ross Ference Carmel LLP Represents Lexaria Bioscience Corp. in a $1.6 Million Registered Direct Offering
Press Release – New York, NY – October 3, 2023 – Sichenzia Ross Ference Carmel LLP announced today that it represented Lexaria Bioscience Corp. (the “Company”), (NASDAQ: LEXX), a global innovator in drug delivery platforms, in a $1.6 million registered direct offering.
The Company has entered into a securities purchase agreement with a single healthcare-focused institutional investor to purchase 1,618,330 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering. In a concurrent private placement, the Company also agreed to issue and sell to the investor warrants to purchase up to 1,618,330 shares of common stock. The combined effective offering price for each share of common stock (or pre-funded warrant in lieu thereof) and accompanying warrant is $0.97. Maxim Group LLC acted as the sole placement agent in connection with the offering.
The Sichenzia Ross Ference Carmel LLP team was led by partners Gregory Sichenzia and Avital Perlman and associate Christian Lichtenberger.